Familial Adenomatous Polyposis Pipeline Landscape Report 2024 [Yahoo! Finance]
Recursion Pharmaceuticals, Inc. (NASDAQ: RXRX) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $11.00 price target on the stock.
Recursion and Exscientia, two leaders in the AI drug discovery space, have officially combined to advance the industrialization of drug discovery
Recursion and Exscientia Shareholders Approve the Proposed Combination
Recursion Announces the Release of OpenPhenom-S/16 in Google Cloud’s Model Garden